QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=C1188DFB6C25D0C9A6AAC30CD302840A;jsessionid=248F3DAA0A3B49CFFA500CD72A63A70F;jsessionid=7DCB1D2D5C088C7A35EC5C67FB5DDFA2;jsessionid=7AB0F09470C76EF81FF4CA17C38B053E;jsessionid=3F703D95099F86E08FD3296AE45AF495;jsessionid=05387E63F564158E6ED7CC6A439F452E;jsessionid=33851257C30897FBE2237B94402AB004;jsessionid=BC76B0A7F194CC6543EE13972FD7146E;jsessionid=10E92C90A34A42994E90F909A54AF52A (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Identification of novel regulatory NFAT and TFII-I binding elements in the calbindin-D28k promoter i…

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=C1188DFB6C25D0C9A6AAC30CD302840A;jsessionid=248F3DAA0A3B49CFFA500CD72A63A70F;jsessionid=7DCB1D2D5C088C7A35EC5C67FB5DDFA2;jsessionid=7AB0F09470C76EF81FF4CA17C38B053E;jsessionid=3F703D95099F86E08FD3296AE45AF495;jsessionid=05387E63F564158E6ED7CC6A439F452E;jsessionid=33851257C30897FBE2237B94402AB004;jsessionid=BC76B0A7F194CC6543EE13972FD7146E;jsessionid=10E92C90A34A42994E90F909A54AF52A